Literature DB >> 27562931

First human case of tick-borne encephalitis virus infection acquired in the Netherlands, July 2016.

Joris A de Graaf1, Johan H J Reimerink, G Paul Voorn, Elisabeth A Bij de Vaate, Ankje de Vries, Barry Rockx, Alie Schuitemaker, Vishal Hira.   

Abstract

In July 2016, the first autochthonous case of tick-borne encephalitis was diagnosed in the Netherlands, five days after a report that tick-borne encephalitis virus (TBEV) had been found in Dutch ticks. A person in their 60s without recent travel history suffered from neurological symptoms after a tick bite. TBEV serology was positive and the tick was positive in TBEV qRT-PCR. TBEV infection should be considered in patients with compatible symptoms in the Netherlands. This article is copyright of The Authors, 2016.

Entities:  

Keywords:  Flaviviridae; emerging diseases; public health; tick-borne diseases; viral encephalitis; viral infections

Mesh:

Substances:

Year:  2016        PMID: 27562931      PMCID: PMC4998423          DOI: 10.2807/1560-7917.ES.2016.21.33.30318

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


Until recently, tick-borne encephalitis virus (TBEV) was thought to be absent in the Netherlands and all cases of tick-borne encephalitis (TBE) were considered imported from endemic regions [1,2]. On 30 June 2016, the Dutch National Institute for Public Health and the Environment (RIVM) reported that Dutch Ixodes ricinus ticks were RT-PCR positive for TBEV-Eu, but no autochthonous cases had been diagnosed at that point [3]. This is the first report of an autochthonous case of TBE in the Netherlands.

Case description

In June 2016, a person in their 60s presented at a hospital in the middle of the Netherlands with complaints of malaise, fatigue, headache, nausea and a subfebrile temperature (37.9 °C) after a tick bite. The malaise and fatigue had started earlier that month (day 0), the other symptoms started two days later. On day 4, the general practitioner discovered a tick on the patient’s left leg, removed it and started antibiotic treatment with doxycycline for 10 days. In retrospect, the bite is most likely to have occurred two days before onset of symptoms in a forested area between Driebergen en Maarn. Initially, the patient improved after antibiotic treatment and the symptoms disappeared. However, on day 12 the patient suffered from tremors, slow speech, weakness and fatigue. Subsequently, these symptoms progressed and fever (40.0 °C), nausea and vomiting developed on day 21. The patient was referred to the hospital on day 24. Neurological and general physical examination revealed no other abnormalities, especially no signs of meningism. Laboratory blood tests showed no specific abnormalities (Table 1), nor did a computed tomography scan of the brain. Serum and cerebrospinal fluid (CSF) tested negative for Lyme borreliosis (Table 2), however, CSF showed a mononuclear cell reaction (Table 1).
Table 1

Clinical, chemical and haematological tests on blood and cerebrospinal fluid at hospital admission, tick-borne encephalitis case, the Netherlands, July 2016*

PatientReference value
Blood
Haemoglobin (mmol/L)7.68.5–11.0
Leukocyte count (109/L)6.94.0–10.0
Thrombocyte count (109/L)211150–400
Erythrocyte sedimentation rate (mm/hour)600–19
Sodium (mmol/L)131135–145
Potassium (mmol/L)3.93.6–5.1
Glucose (mmol/L)6.14.0–7.0
C-reactive protein (mg/L)120–10
Cerebrospinal fluid
Polynuclear cells (cells/µL)2Not applicable
Mononuclear cells (cells /µL)61Not applicable
Erythrocytes (cells /µL)128Not applicable
Glucose (mmol/L)3.52.0–4.0
Protein (g/L)0.890.15–0.45
Table 2

Performed tests for infectious diseases, tick-borne encephalitis case, the Netherlands, July 2016*

BloodCerebrospinal fluid
Bartonella henselae IgM negativeND
Borrelia burgdorferi C6 IgG negative IgG negative IgM negativePCR negative serum/liquor index IgM and IgG negative
Treponema pallidum Serological screening negativeND
TuberculosisIGRA negativeND
HIVSerological screening negativeND
EnterovirusNDPCR negative
ParechovirusNDPCR negative
Herpes simplex virus 1 and 2NDPCR negative
Varicella zoster virusNDPCR negative

HIV: human immunodificiency virus; IGRA: interferon gamma release assay; ND: Not done; PCR: polymerase chain reaction.

HIV: human immunodificiency virus; IGRA: interferon gamma release assay; ND: Not done; PCR: polymerase chain reaction. Additional diagnostic tests were conducted to exclude other infectious diseases (Table 2). Although TBE was not considered endemic in the Netherlands, it was added to the differential diagnosis after the RIVM reported that TBEV had been detected in ticks in the eastern part of the country (Sallandse Heuvelrug), 100 km from Driebergen [3]. In 2016, the patient had not travelled to the Sallandse Heuvelrug or any other regions known to be endemic for TBE. Their last stay abroad had been in October 2015, in Paderborn, Germany, which is not a region endemic for TBEV [4]. They had not visited other places abroad in the past five years. The patient was not vaccinated against TBEV, but had received a vaccination against yellow fever virus in 2005. Serum taken on day 24 and 36 was positive for anti-TBEV IgM (452 and 162 Vienna units (VIEU)/mL, respectively; cut-off: 63 VIEU/mL) and IgG (> 650 and > 650 VIEU/mL, respectively; cut-off: 100 VIEU/mL) (Progen Biotechnik). CSF was negative for IgM but IgG-positive. In addition, both sera were positive in a TBEV neutralisation assay (1/640). A TBEV-specific qRT-PCR on CSF, blood and urine was negative. Fortunately, the patient had saved the dead tick, which was was positive for TBEV by qRT-PCR with a Ct value of 21. Interestingly, based on comparison of partial NS5 sequences of the PCR products, TBEV in the patient’s tick showed 93% homology with those found in Sallandse Heuvelrug, but 99% homology with a prototype TBEV-Eu Neudörfl strain. During clinical observation, the patient gradually improved. At discharge on day 37, no focal neurological deficits were present, but fatigue and mild subjective cognitive complaints (Montreal Cognitive Assessment 26/30) remained.

Discussion

This is the first report of a case of TBE in a patient infected in the Netherlands. Although liquor was negative for anti-TBEV IgM antibodies, the high serum IgM and IgG levels in an unvaccinated patient, combined with a typical biphasic clinical presentation and TBEV detected in the tick collected from the patient, confirmed the diagnosis of TBE [5]. Since the patient had not travelled abroad in the previous seven months, they must have been infected in the Netherlands, as the incubation period for TBE is no longer than a month and Ixodes species only feed for several days per host [1,6]. TBE is considered an emerging disease due to its rising incidence and the expansion in new, previously uninfected, areas but until now, autochthonous human TBEV infection had not been reported in the Netherlands [3,7]. The presence of TBEV in ticks collected in the Netherlands was recently confirmed [3]. Interestingly, preliminary sequence data suggest that the TBEV detected in the tick from our patient had a higher homology to the prototype TBEV-Eu strain Neudörfl than to those found in the Sallandse Heuvelrug. The Neudörlf strain and related TBEV strains have been found throughout Europe, including Germany. Although it is highly likely that the TBEV-infected tick that bit our patient was acquired between Driebergen and Maarn, the exact origin of the tick requires further investigation. Further studies are needed to determine the geographic spread and genetic diversity of TBEV in ticks in the Netherlands. This case is an excellent example of the importance of tenacity and persistence in difficult diagnostic cases. Looking beyond guidelines and current evidence can lead to new findings, which can be beneficial not only for the individual patient but also for public health. Surveillance and widespread messages by public health institutes can be of great value to the diagnostic process, as they can provide clinicians with clues for the diagnosis of disease in individual patients. This case has important implications. On a patient level, clinicians in the Netherlands need to add TBE to the differential diagnosis for patients hospitalised with (meningo)encephalitis or meningitis who may have been exposed to tick bites. On a public health level, further studies are needed to determine the extent of TBEV infections in humans in the Netherlands. These studies include surveillance of TBEV in humans, animals and ticks, as well as determining the risk of acquiring TBEV infection by serosurveillance studies in the general population, patient populations with unknown neurological disease and for professions at high risk for tick bites.
  5 in total

Review 1.  Diagnosis of tick-borne encephalitis.

Authors:  Heidemarie Holzmann
Journal:  Vaccine       Date:  2003-04-01       Impact factor: 3.641

Review 2.  Ticks and tickborne bacterial diseases in humans: an emerging infectious threat.

Authors:  P Parola; D Raoult
Journal:  Clin Infect Dis       Date:  2001-03-14       Impact factor: 9.079

3.  Case report: tick-borne encephalitis in two Dutch travellers returning from Austria, Netherlands, July and August 2011.

Authors:  C Reusken; J Reimerink; C Verduin; L Sabbe; N Cleton; M Koopmans
Journal:  Euro Surveill       Date:  2011-11-03

4.  Tick-borne encephalitis-still on the map: Report of the 18th annual meeting of the international scientific working group on tick-borne encephalitis (ISW-TBE).

Authors:  Ursula Kunze
Journal:  Ticks Tick Borne Dis       Date:  2016-05-06       Impact factor: 3.744

Review 5.  Tick-borne encephalitis virus - a review of an emerging zoonosis.

Authors:  K L Mansfield; N Johnson; L P Phipps; J R Stephenson; A R Fooks; T Solomon
Journal:  J Gen Virol       Date:  2009-05-06       Impact factor: 3.891

  5 in total
  16 in total

1.  Integrative RNA profiling of TBEV-infected neurons and astrocytes reveals potential pathogenic effectors.

Authors:  Martin Selinger; Pavlína Věchtová; Hana Tykalová; Petra Ošlejšková; Michaela Rumlová; Ján Štěrba; Libor Grubhoffer
Journal:  Comput Struct Biotechnol J       Date:  2022-05-30       Impact factor: 6.155

2.  Human Tick-Borne Encephalitis, the Netherlands.

Authors:  Vishal Hira; Barry Rockx
Journal:  Emerg Infect Dis       Date:  2017-01-15       Impact factor: 6.883

3.  Prevention of tick bites: an evaluation of a smartphone app.

Authors:  L Antonise-Kamp; D J M A Beaujean; R Crutzen; J E van Steenbergen; D Ruwaard
Journal:  BMC Infect Dis       Date:  2017-12-04       Impact factor: 3.090

4.  Increasing evidence of tick-borne encephalitis (TBE) virus transmission, the Netherlands, June 2016.

Authors:  Adriaan Cg Weststrate; Daan Knapen; Gozewijn D Laverman; Bart Schot; Jan Jw Prick; Silke A Spit; Johan Reimerink; Barry Rockx; Felix Geeraedts
Journal:  Euro Surveill       Date:  2017-03-16

Review 5.  Neglected aspects of tick-borne rickettsioses.

Authors:  Laura Tomassone; Aránzazu Portillo; Markéta Nováková; Rita de Sousa; José Antonio Oteo
Journal:  Parasit Vectors       Date:  2018-04-24       Impact factor: 3.876

6.  Tick-borne encephalitis in Europe, 2012 to 2016.

Authors:  Julien Beauté; Gianfranco Spiteri; Eva Warns-Petit; Hervé Zeller
Journal:  Euro Surveill       Date:  2018-11

7.  First paediatric case of autochthonous tick-borne encephalitis in the Netherlands, 2018.

Authors:  F Geeraedts; E van der Kroft; J Reimerink
Journal:  New Microbes New Infect       Date:  2019-09-19

8.  Letter to the editor: The first tick-borne encephalitis case in the Netherlands: reflections and a note of caution.

Authors:  Jan Clement; Katrien Lagrou; Veroniek Saegeman; Piet Maes; Marc van Ranst
Journal:  Euro Surveill       Date:  2016-09-29

9.  Tick-Borne Encephalitis Virus in Ticks and Roe Deer, the Netherlands.

Authors:  Setareh Jahfari; Ankje de Vries; Jolianne M Rijks; Steven Van Gucht; Harry Vennema; Hein Sprong; Barry Rockx
Journal:  Emerg Infect Dis       Date:  2017-06       Impact factor: 6.883

10.  Tick-Borne Encephalitis Virus Antibodies in Roe Deer, the Netherlands.

Authors:  Jolianne M Rijks; Margriet G E Montizaan; Nine Bakker; Ankje de Vries; Steven Van Gucht; Corien Swaan; Jan van den Broek; Andrea Gröne; Hein Sprong
Journal:  Emerg Infect Dis       Date:  2019-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.